Search details
1.
Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.
Crit Care Med
; 42(3): 504-11, 2014 Mar.
Article
in English
| MEDLINE | ID: mdl-24335445
2.
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.
Breast Cancer Res Treat
; 138(1): 149-55, 2013 Feb.
Article
in English
| MEDLINE | ID: mdl-23378064
3.
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Cancer Res
; 83(23): 3989-4004, 2023 12 01.
Article
in English
| MEDLINE | ID: mdl-37725704
4.
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.
Breast Cancer Res Treat
; 136(2): 503-11, 2012 Nov.
Article
in English
| MEDLINE | ID: mdl-23065000
5.
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
Mol Oncol
; 16(10): 1969-1985, 2022 05.
Article
in English
| MEDLINE | ID: mdl-34866317
6.
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
NPJ Breast Cancer
; 7(1): 44, 2021 Apr 16.
Article
in English
| MEDLINE | ID: mdl-33863913
7.
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).
Breast Cancer Res Treat
; 123(2): 453-61, 2010 Sep.
Article
in English
| MEDLINE | ID: mdl-20632084
8.
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.
Clin Cancer Res
; 26(15): 3947-3957, 2020 08 01.
Article
in English
| MEDLINE | ID: mdl-32312891
9.
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer.
Clin Cancer Res
; 26(16): 4242-4249, 2020 08 15.
Article
in English
| MEDLINE | ID: mdl-32234755
10.
Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
Clin Cancer Res
; 26(7): 1574-1585, 2020 04 01.
Article
in English
| MEDLINE | ID: mdl-31836609
11.
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.
Cancer Discov
; 10(10): 1528-1543, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32532747
12.
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2- Advanced Breast Cancer.
Clin Cancer Res
; 24(15): 3510-3518, 2018 08 01.
Article
in English
| MEDLINE | ID: mdl-29440181
13.
A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.
Cancer Chemother Pharmacol
; 81(5): 873-883, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29541803
14.
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.
Clin Cancer Res
; 24(23): 5860-5872, 2018 12 01.
Article
in English
| MEDLINE | ID: mdl-30082476
15.
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.
Clin Cancer Res
; 24(9): 2050-2059, 2018 05 01.
Article
in English
| MEDLINE | ID: mdl-29066505
16.
Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients.
PLoS One
; 12(5): e0175779, 2017.
Article
in English
| MEDLINE | ID: mdl-28472036
17.
Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363.
J Natl Cancer Inst
; 109(3): 1-4, 2017 03 01.
Article
in English
| MEDLINE | ID: mdl-28376212
18.
Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
Clin Cancer Res
; 28(24): 5469, 2022 Dec 15.
Article
in English
| MEDLINE | ID: mdl-36519303
19.
AKT Inhibition in Solid Tumors With AKT1 Mutations.
J Clin Oncol
; 35(20): 2251-2259, 2017 Jul 10.
Article
in English
| MEDLINE | ID: mdl-28489509
20.
Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 77(4): 787-95, 2016 Apr.
Article
in English
| MEDLINE | ID: mdl-26931343